Lead with the number, then the call color. In its annual report for fiscal 2020, filed February 26, 2021, Moderna disclosed that it held approximately $5.25 billion in cash, cash equivalents and investments at December 31, 2020. For a company that spent years pre-revenue, that is the headline fact: the platform is now funded at a scale it had never previously commanded.
The income statement tells the matching story. Full-year 2020 revenue came in at about $803 million, with research and development expense of roughly $1.37 billion. Revenue arrived in force for the first time, even as R&D nearly doubled the top line — the company is spending heavily to push its broader pipeline while a product begins to generate cash.
The fundamentals-first read is that 2020 is the inflection year on paper: a clinical-stage platform crossing into commercial-stage economics. The cash cushion changes the financing calculus that defined Moderna’s earlier life — with billions on the balance sheet, the company is no longer dependent on continuous dilution simply to keep its programs alive.
Read forward from this filing, the question that the 10-K cannot answer is durability: whether the revenue that appeared in 2020 persists, and what the company does with a war chest of this size across the rest of its pipeline. As of February 2021, the document records the transition, not its outcome.
Every figure above is drawn from the company's primary SEC filing — surfaced through EdgarBeast, the SEC filing data API and evidence index — and verifiable against the filing on sec.gov.